TICKERNOMICS Sign up
Last Update: 2024-12-27 15:26:29
aTYR PHARMA INC ( ATYR ) https://www.atyrpharma.com
3.77USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
ATYR
156.46%
SPY
32.66%
-49.05%
ATYR
SPY
108.59%
-11.71%
ATYR
SPY
302.52%
ATYR
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
285.77
231.80
0.99
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-4.48
486.01
4.39
-53.35
0.00
-3.39
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-7368.09
-162.98
-7266.81
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
10.208
-242.53
-75.46
1.60
Other Earnings and Cash Flow Stats:
aTYR PHARMA INC ( ATYR ) Net Income TTM ($MM) is -63.82
aTYR PHARMA INC ( ATYR ) Operating Income TTM ($MM) is -68.05
aTYR PHARMA INC ( ATYR ) Owners' Earnings Annual ($MM) is 0.00
aTYR PHARMA INC ( ATYR ) Current Price to Owners' Earnings ratio is 0.00
aTYR PHARMA INC ( ATYR ) EBITDA TTM ($MM) is -66.10
aTYR PHARMA INC ( ATYR ) EBITDA Margin is -7266.81%
Capital Allocation:
aTYR PHARMA INC ( ATYR ) has paid 0.00 dividends per share and bought back -17.916273 million shares in the past 12 months
aTYR PHARMA INC ( ATYR ) has increased its debt by 12.014 million USD in the last 12 months
Capital Structure:
aTYR PHARMA INC ( ATYR ) Interest-bearing Debt ($MM) as of last quarter is 12
aTYR PHARMA INC ( ATYR ) Annual Working Capital Investments ($MM) are -71
aTYR PHARMA INC ( ATYR ) Book Value ($MM) as of last quarter is 65
aTYR PHARMA INC ( ATYR ) Debt/Capital as of last quarter is 18%
Other Balance Sheet Stats:
aTYR PHARMA INC ( ATYR ) has 11 million in cash on hand as of last quarter
aTYR PHARMA INC ( ATYR ) has 14 million of liabilities due within 12 months, and long term debt 0 as of last quarter
aTYR PHARMA INC ( ATYR ) has 75 common shares outstanding as of last quarter
aTYR PHARMA INC ( ATYR ) has 0 million USD of preferred stock value
Academic Scores:
aTYR PHARMA INC ( ATYR ) Altman Z-Score is -3.13 as of last quarter
aTYR PHARMA INC ( ATYR ) Piotroski Score is 0.00 as of last quarter
Corporate Governance:
aTYR PHARMA INC ( ATYR ) largest shareholder is owning shares at 0.00 ($MM) value
(an insider) shares of aTYR PHARMA INC ( ATYR ) for the amount of $ on
2.39% of aTYR PHARMA INC ( ATYR ) is held by insiders, and 64.48% is held by institutions
aTYR PHARMA INC ( ATYR ) went public on 2015-05-07
Other aTYR PHARMA INC ( ATYR ) financial metrics:
FCF:-67.11
Unlevered Free Cash Flow:0.00
EPS:-0.91
Operating Margin:-7368.09
Gross Profit Margin:-162.98
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-105.68
Beta:1.60
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About aTYR PHARMA INC ( ATYR ) :
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.